Nothing Special   »   [go: up one dir, main page]

WO2009103788A9 - Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres - Google Patents

Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres Download PDF

Info

Publication number
WO2009103788A9
WO2009103788A9 PCT/EP2009/052038 EP2009052038W WO2009103788A9 WO 2009103788 A9 WO2009103788 A9 WO 2009103788A9 EP 2009052038 W EP2009052038 W EP 2009052038W WO 2009103788 A9 WO2009103788 A9 WO 2009103788A9
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
phytoestrogens
selective
dietary fibres
beta receptor
Prior art date
Application number
PCT/EP2009/052038
Other languages
French (fr)
Other versions
WO2009103788A1 (en
Inventor
Alfredo Di Leo
Michele Barone
Original Assignee
Cm & D Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200980105957XA priority Critical patent/CN101951900A/en
Priority to DK09712828.4T priority patent/DK2254573T5/en
Priority to NZ587116A priority patent/NZ587116A/en
Priority to BRPI0908493A priority patent/BRPI0908493A2/en
Priority to ES09712828T priority patent/ES2387530T3/en
Priority to AU2009216653A priority patent/AU2009216653B2/en
Priority to JP2010547188A priority patent/JP2011512386A/en
Application filed by Cm & D Pharma Limited filed Critical Cm & D Pharma Limited
Priority to EP09712828A priority patent/EP2254573B9/en
Priority to MX2010009021A priority patent/MX2010009021A/en
Priority to CA2714668A priority patent/CA2714668C/en
Priority to EA201001343A priority patent/EA020095B1/en
Priority to US12/867,434 priority patent/US20110027230A1/en
Priority to UAA201010940A priority patent/UA101178C2/en
Publication of WO2009103788A1 publication Critical patent/WO2009103788A1/en
Publication of WO2009103788A9 publication Critical patent/WO2009103788A9/en
Priority to IL207670A priority patent/IL207670A/en
Priority to ZA2010/06767A priority patent/ZA201006767B/en
Priority to HK11104932.0A priority patent/HK1151457A1/en
Priority to US14/106,683 priority patent/US20140105864A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-β, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.
PCT/EP2009/052038 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres WO2009103788A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
UAA201010940A UA101178C2 (en) 2008-02-22 2009-02-20 Composition comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
NZ587116A NZ587116A (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
BRPI0908493A BRPI0908493A2 (en) 2008-02-22 2009-02-20 compositions comprising selective estrogen receptor beta phytoestrogens and dietary fibers
ES09712828T ES2387530T3 (en) 2008-02-22 2009-02-20 Compositions comprising selective phytoestrogens for the estrogen and food fiber beta receptor
AU2009216653A AU2009216653B2 (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
JP2010547188A JP2011512386A (en) 2008-02-22 2009-02-20 Composition containing estrogen receptor β selective phytoestrogens and dietary fiber
CA2714668A CA2714668C (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
EP09712828A EP2254573B9 (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
MX2010009021A MX2010009021A (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres.
CN200980105957XA CN101951900A (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
EA201001343A EA020095B1 (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
US12/867,434 US20110027230A1 (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogenes selective for estrogen beta receptor and dietary fibres
DK09712828.4T DK2254573T5 (en) 2008-02-22 2009-02-20 COMPOSITIONS COMPREHENSIVE PHYTO ESTROGENS SELECTIVE FOR ESTROGEN BETTERY RECEPTOR AND DIET FIBERS
IL207670A IL207670A (en) 2008-02-22 2010-08-18 Compositions comprising phytoestrogens selectively agonist to the estrogen beta receptor and dietary fibres and use thereof for preparation of medicaments for treating intestinal mucosa pathological conditions
ZA2010/06767A ZA201006767B (en) 2008-02-22 2010-09-21 Compositions comprising phytoesrogens selective for estrogen beta receptor and dietary fibres
HK11104932.0A HK1151457A1 (en) 2008-02-22 2011-05-18 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
US14/106,683 US20140105864A1 (en) 2008-02-22 2013-12-13 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBA2008A000008 2008-02-22
IT000008A ITBA20080008A1 (en) 2008-02-22 2008-02-22 COMPOSITIONS INCLUDING SELECTIVE PHYTO-EXTERGENS FOR THE ESTROGENIC BETA AND DIETARY FIBER RECEPTOR

Publications (2)

Publication Number Publication Date
WO2009103788A1 WO2009103788A1 (en) 2009-08-27
WO2009103788A9 true WO2009103788A9 (en) 2010-02-04

Family

ID=40291378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/052038 WO2009103788A1 (en) 2008-02-22 2009-02-20 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres

Country Status (20)

Country Link
US (2) US20110027230A1 (en)
EP (1) EP2254573B9 (en)
JP (1) JP2011512386A (en)
KR (1) KR20100131985A (en)
CN (1) CN101951900A (en)
BR (1) BRPI0908493A2 (en)
CA (1) CA2714668C (en)
CO (1) CO6361919A2 (en)
DK (1) DK2254573T5 (en)
EA (1) EA020095B1 (en)
ES (1) ES2387530T3 (en)
IL (1) IL207670A (en)
IT (1) ITBA20080008A1 (en)
MX (1) MX2010009021A (en)
MY (1) MY150407A (en)
NZ (1) NZ587116A (en)
PT (1) PT2254573E (en)
UA (1) UA101178C2 (en)
WO (1) WO2009103788A1 (en)
ZA (1) ZA201006767B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045068A1 (en) 2011-09-30 2013-04-04 Cm&D Pharma Limited Compositions comprising phytoestrogens receptor beta agonists and dietary fibres for chemopreventive treatment of sporadic adenomatous polyposis
KR101166798B1 (en) * 2011-12-19 2012-07-26 김대현 Pharmaceutical compositions for treating or preventing allergic diseases comprising dead cells of lactobacillus acidoohilus lb
ITMI20122270A1 (en) * 2012-12-31 2014-07-01 Giovanni Mogna THERAPY SUPPORTING CHEMOTHERAPY TREATMENTS FOR CANCER, FOR THE IMMUNO-DEFICIENCY SYNDROME ACQUIRED AND FOR LEUCEMIES.
US20150098978A1 (en) * 2013-10-03 2015-04-09 Altria Client Services Inc. Dissolvable-chewable tablet
MY186844A (en) 2014-07-09 2021-08-25 Cadena Bio Inc Oligosaccharide compositions and methods for producing thereof
EP4205553A1 (en) 2015-01-26 2023-07-05 DSM Nutritional Products, LLC Oligosaccharide compositions for use animal feed and methods of producing thereof
CN107771083A (en) 2015-04-23 2018-03-06 卡莱多生物科技有限公司 Glycan therapeutic agent and treatment method
WO2017069293A1 (en) * 2015-10-19 2017-04-27 주식회사 파미니티 Functional composition for improvement and prevention of estrogen deficiency in menopausal women
CN106822217B (en) * 2017-02-20 2020-05-05 天津医科大学总医院 Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis
GB201708932D0 (en) * 2017-06-05 2017-07-19 Probi Ab Microbial compositions
WO2020161522A1 (en) 2019-02-06 2020-08-13 Thd S.P.A. Fiber-based composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9625129D0 (en) 1996-12-03 1997-01-22 Cerestar Holding Bv Highly fermentable resistant starch
JP3497362B2 (en) * 1997-11-12 2004-02-16 株式会社朝日商事 Anticancer drugs
AU770075B2 (en) * 1999-02-24 2004-02-12 Mars, Incorporated Dietary compositions and methods
WO2001021165A1 (en) * 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
AU2002366638A1 (en) * 2001-12-06 2003-06-23 Scolr Pharma, Inc. Isoflavone composition for oral delivery
US7238373B2 (en) * 2003-04-04 2007-07-03 Nutritox Llc Nutritional supplement
CZ295149B6 (en) * 2003-11-10 2005-06-15 Naturprodukt Cz Spol. S R. O. Silymarin-based food supplement
US20050238654A1 (en) * 2004-04-26 2005-10-27 Yoshinori Takeda Compositions and methods for weight loss
KR100592717B1 (en) * 2004-11-20 2006-06-26 주식회사 알엔에이 Composition having preventive and therapeutic effects of liver damage
WO2007140613A1 (en) * 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof

Also Published As

Publication number Publication date
ES2387530T9 (en) 2013-01-15
AU2009216653A1 (en) 2009-08-27
CA2714668C (en) 2017-01-10
US20140105864A1 (en) 2014-04-17
CO6361919A2 (en) 2012-01-20
EP2254573B1 (en) 2012-05-16
EP2254573A1 (en) 2010-12-01
UA101178C2 (en) 2013-03-11
EP2254573B9 (en) 2012-09-26
IL207670A (en) 2013-12-31
BRPI0908493A2 (en) 2019-09-24
IL207670A0 (en) 2010-12-30
ITBA20080008A1 (en) 2009-08-23
CN101951900A (en) 2011-01-19
ZA201006767B (en) 2011-06-29
US20110027230A1 (en) 2011-02-03
MX2010009021A (en) 2010-11-12
DK2254573T3 (en) 2012-08-20
KR20100131985A (en) 2010-12-16
PT2254573E (en) 2012-08-08
EA201001343A1 (en) 2011-02-28
EA020095B1 (en) 2014-08-29
JP2011512386A (en) 2011-04-21
NZ587116A (en) 2012-02-24
WO2009103788A1 (en) 2009-08-27
CA2714668A1 (en) 2009-08-27
MY150407A (en) 2014-01-15
DK2254573T5 (en) 2012-09-17
ES2387530T3 (en) 2012-09-25

Similar Documents

Publication Publication Date Title
WO2009103788A9 (en) Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
WO2007131736A3 (en) Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
GEP20104994B (en) Tetrahydroindolone and tetrahydroindazolone derivatives
EP1937845A4 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2008134474A3 (en) Compositions and methods including cell death inducers and procaspase activation
WO2007127010A3 (en) Diarylthiohydantoin compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
MX2010009670A (en) Polymer paclitaxel conjugates and methods for treating cancer.
WO2008024977A3 (en) Isoquinoline, quinazoline and phthalazine derivatives
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2011041336A3 (en) Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
MY146112A (en) Long-term feed - cancer patient
UA100684C2 (en) Normal;heading 1;heading 2;heading 3;BENZYL AND PYRIDINYL DERIVATIVES AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY
WO2008046085A3 (en) Quinoline derivatives for modulating dna methylation
HK1112856A1 (en) Diarylhydantoin compound
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2010028187A3 (en) Methods and compositions for the treatment of cancer
FR2921927B1 (en) IMIDAZO® 1,2-A! QUINOXALINS AND DERIVATIVES FOR THE TREATMENT OF CANCER
TNSN07294A1 (en) Treatment of metastasized tumors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980105957.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712828

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009216653

Country of ref document: AU

Ref document number: 587116

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12867434

Country of ref document: US

Ref document number: 2714668

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/009021

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 207670

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2009216653

Country of ref document: AU

Date of ref document: 20090220

Kind code of ref document: A

Ref document number: 20107018463

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010547188

Country of ref document: JP

Ref document number: 12010501905

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PI 2010003728

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 10116255

Country of ref document: CO

Ref document number: 5867/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009712828

Country of ref document: EP

Ref document number: 201001343

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0908493

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100823